Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

173.30GBp
11:38am EDT
Change (% chg)

1.30p (+0.76%)
Prev Close
172.00p
Open
174.70p
Day's High
176.20p
Day's Low
171.00p
Volume
1,970,038
Avg. Vol
704,613
52-wk High
200.10p
52-wk Low
145.30p

VEC.L

Chart for VEC.L

About

Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to... (more)

Overall

Beta: 0.37
Market Cap(Mil.): £706.11
Shares Outstanding(Mil.): 410.53
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): 110.33 34.06 44.92
EPS (TTM): 0.02 -- --
ROI: 2.70 13.00 12.47
ROE: 3.04 13.69 13.34
Search Stocks

Drugmaker Vectura Group to buy SkyePharma

March 16 Drugmaker Vectura Group said on Wednesday it would buy SkyePharma Plc in an all-stock deal that would give it SkyePharma's drug delivery platform.

Mar 16 2016

BRIEF-HBM Healthcare Investments says Skyepharma to merge with Vectura group

* Under the terms of the proposed merger, Skyepharma shareholders will be entitled to receive 2.7977 new Vectura shares for every Skyepharma share

Mar 16 2016

BRIEF-Vectura Group to buy Skyepharma for 441.3 million stg

* Vectura Group and Skyepharma Plc have reached agreement on terms of a recommended merger between Vectura and Skyepharma

Mar 16 2016

BRIEF-Vectura says clinical study report for asthma therapy VR315 now final

* Next planned milestone and announcement scheduled for this programme is $10 million due to be paid upon acceptance for filing of ANDA by FDA

Feb 10 2016

BRIEF-Vectura completes clinical trial for asthama therapy

* Is eligible to receive a further $23 mln upon achievement of future pre-determined development milestones on VR315 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Jan 08 2016

BRIEF-Vectura says to receive milestone payment of $3.75 mln

* Commencement of first phase III trial of inhaled triple therapy QVM149 for asthma and milestone payment

Dec 09 2015

BRIEF-Vectura posts smaller half-year pretax loss

* Half year pretax loss 5 mln stg vs 6.2 mln stg loss year ago

Nov 17 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : GlobalData
$300.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Sadif Analytics Prime
$10.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks